Seagen Inc. v. Daiichi Sankyo Co., Ltd.

  1. October 20, 2020

    Daiichi Faces Patent Suit Over New Breast Cancer Drug

    Daiichi Sankyo is facing claims in Texas federal court that its recently approved breast cancer treatment drug, which has allegedly earned the Japanese pharmaceutical giant $70 million in sales, infringes a U.S. biotechnology company's patent.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!